Unique immune signatures in IDH-mutant gliomas correlate with prognosis, revealing potential therapeutic targets (ref: Sussman doi.org/10.1093/neuonc/).
Vorasidenib shows improved progression-free survival in IDH-mutant astrocytomas, marking a significant treatment advancement (ref: Barbato doi.org/10.1158/1078-0432.CCR-25-1333/).
Tumor volumes at malignant transformation differ significantly in IDH-mutant gliomas, suggesting imaging biomarkers for clinical decision-making (ref: Cho doi.org/10.1093/neuonc/).
Extent of resection guidelines emphasize the importance of surgical strategies tailored to individual glioma characteristics (ref: Goldbrunner doi.org/10.1093/neuonc/).
Glutamate and glutamine concentrations in gliomas correlate with tumor characteristics and may inform treatment strategies (ref: Hangel doi.org/10.1148/rycan.240494/).
Tumor heterogeneity significantly impacts clinical outcomes and responses to targeted therapies in glioblastomas (ref: Pan doi.org/10.1172/jci.insight.192658/).
Health state utilities for IDH-mutant gliomas provide valuable data for economic evaluations and treatment planning (ref: Howard doi.org/10.1007/s41669-025-00603-0/).
Multiparametric ultrasound shows promise in predicting IDH mutations, aiding in glioma molecular subtyping (ref: Cai doi.org/10.3390/jcm14176264/).